PubMed Health⌕ Search

Biomedical subjects

G Abate

Publications and source records attributed to G Abate.

At least 19 recordsLinked to original sources
PubMed1992

Effect of ipriflavone on bone mass in elderly osteoporotic women.

A study in elderly osteoporotic women was performed to assess the effect of one year treatment with ipriflavone (IP) on bone mass and bone biomarkers. Twenty-eight women aged over 65, with diagnosis of osteoporosis and X-ray evidence of at least one vertebral fracture, were treated with IP tablets (600 mg/day) or placebo (PL), according to a randomized, double-blind, parallel-group design. One g/day calcium supplementation was given to all patients. After 12 months a significant increase (+6%, P < 0.05) of bone mineral density (BMD) at the distal radius (DPA) was obtained in the IP-group. Serum osteocalcin (BGP) and urinary HO-proline/creatinine (HOP/Cr) values were reduced in the same group. BMD values did not change (-0.3%) in the placebo group. One woman of the PL-group was withdrawn from treatment because of worsening of pain, due to new vertebral crushes. Side effects (mainly gastrointestinal) arose in 8 IP- and in 5 PL-treated women. The compliance to the oral administration was good.

Aged↗
PubMed1992

[Epidemiologic study on the effectiveness and safety of dihydroergocristine in impaired memory and behavioral functions in aged humans].

Aim of the study was to assess the activity of dihydroergocristine (DHEC, CAS 17479-19-5) in aged patients with impaired cognitive function. Twenty-five university hospital centres and 250 physicians participated in the study. 2,600 patients (1,104 males and 1,496 females, age range 50-80 years) were admitted to the study. Each patient was administered 6 mg/d DHEC for 120 days. Clinical evaluation was made through the SCAG Rating Scale registered at basal time, after 60 and 120 days. Responsivity to treatment was considered high when the final score was reduced by 30% and none if less than 10%. Analysis of results demonstrated that at the end of the study responsivity was high in 73% of cases, moderate in 20.4% and absent in 6.5%. Tolerability was very good as side effects were reported only in 3.16% of patients. Most frequent side effects were: nausea (1.23%), gastralgia (1.11%), headache (0.29%), hypotension (0.12%), vertigo (0.12%) and rash (0.08%). Drop-outs for gastralgia were reported only in 0.53% of the patients.

Aged↗
PubMed1992

The effects of sodium depletion on ambulatory blood pressure and heart rate monitoring in the elderly.

OBJECTIVE: Old age is associated with impairment of the normal homeostatic response to cardiovascular stress. The purpose of our study was to determine whether a physiologic stress, such as sodium depletion, produces different, age-dependent effects on the blood pressure and heart rate profile in old and young subjects. DESIGN: Blood pressure and the heart rate were studied in 11 young (age 28.7 +/- 3.1 years) and 14 elderly (76.1 +/- 3.4 years) male healthy volunteers, during ambulatory blood pressure monitoring and during postural stress before and after 2 days of sodium depletion. METHODS: Twenty-four-hour blood pressure monitoring was performed with a non-invasive automatic portable monitoring device. The postural evaluation consisted of a standard passive upright-tilt test to 70 degrees. Sodium depletion was obtained with a low-salt diet and diuretic treatment (100 mg hydrochlorothiazide) for 2 days. RESULTS: After sodium depletion no changes were found in the average blood pressure. The postural evaluation showed a fall in systolic blood pressure only in the elderly. The heart rate increased only in the young group, both during the ambulatory blood pressure monitoring and after the upright tilt. CONCLUSIONS: These results suggest that cardiovascular reserve is decreased in the elderly under a stress condition such as sodium depletion; this phenomenon may be linked to a blunted baroreceptor reflex response.

Adult↗
PubMed1991

Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study.

One hundred and nine elderly patients suffering from mild to moderate cognitive impairment fulfilling NINCDS-ADRDA criteria for probable dementia of the Alzheimer type were treated for 6 months with a new nootropic drug, aniracetam (Ro 13-5057) in a double-blind randomized study versus placebo. The two treatment groups were comparable at baseline for demographic and behaviourial parameters and symptomatology. Patients underwent clinical, behaviourial and psychometric evaluation every other month. The aniracetam group differed significantly from the placebo group by the end of the study and also showed a statistically significant improvement versus baseline in the psychobehavioural parameters, while in the placebo group a steady deterioration was observed. Tolerability to aniracetam was excellent.

Aged↗
PubMed1991

Effects of antihypertensive therapy with lacidipine on ambulatory blood pressure in the elderly.

Recent multicenter trials have demonstrated that, in hypertensive elderly people, blood pressure control can significantly decrease the rate of cardiovascular and cerebrovascular events. Twenty-four-hour ambulatory blood pressure monitoring has proved to be superior to isolated sphygmomanometer blood pressure readings in the diagnostic evaluation of hypertension and in assessing the blood pressure response to treatment. We used 24-h ambulatory monitoring in a small, double-blind, randomly-allocated, placebo-controlled, parallel-group study of antihypertensive treatment with lacidipine given once a day at 2 or 4 mg. In our elderly subjects, the lacidipine treatment provided adequate blood pressure control both by day and by night with no effect on the heart rate profile. Furthermore, after drug therapy, we found a significant reduction in systolic blood pressure variability (standard deviation). This study shows that lacidipine can provide adequate control of arterial hypertension in the elderly.

Aged↗
PubMed1991

[Controlled multicenter study on the therapeutic effectiveness of mesoglycan in patients with cerebrovascular disease].

One hundred and forty-five elderly patients affected by cerebrovascular diseases were included in the study. Patients were divided into two age-, sex- and clinically matched groups: the first group included 103 patients who were treated for six months with mesoglycan (100 mg/day), whereas the second group, which numbered 42 patients, received standard anti-platelet treatment over the same period. The results of the study confirm the clinical efficacy of mesoglycan compared to standard treatment with antiplatelet drugs in terms of ischemic events and the "quality of life" of cerebrovasculopathic patients.

Aged↗
PubMed1990

Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin.

A combination of cisplatin (60 mg/m2 i.v. on day 1), etoposide (100 mg/m2 i.v. on days 1-3) and bleomycin (15 mg i.v. on days 1 and 8) (PEB regimen) was given every 4 weeks as salvage therapy in 10 refractory and 13 relapsing patients with poor-prognosis non-Hodgkin's lymphomas. All but one of these patients had previously been treated with anthracycline-containing combination chemotherapy. We observed 4 complete remissions (CRs) and 4 partial responses (PRs), whereas 3 patients showed only a minor response (MR) and 12 were considered to be induction failures. Therefore, the objective (CR + PR) response rate was 35%. The most frequent side effect was vomiting, registered in all patients despite antiemetic treatment. Hematologic toxicity was of moderate degree, and bone marrow recovery was observed after almost all cycles after a 3-week rest period. Since objective responses were achieved only in relapsing patients, the PEB regimen seemed to be effective in these cases, whereas it was useless in early refractory non-Hodgkin's lymphomas.

Adult↗
PubMed1979

Effects of indomethacin on postural hypotension in Parkinsonism.

A study was conducted to evaluate the effect of indomethacin on orthostatic hypotension in Parkinsonism. Twelve elderly patients participated and the drug was given in two-ways--as an intravenous infusion of 50 mg over 30 minutes and by mouth 50 mg thrice daily for six days. Results were assessed by measuring the degree of hypotension on standing, response to the cold pressor test, and forearm blood flow (by strain-gauge plethysmography). Indomethacin significantly reduced the fall in blood pressure on standing (P less than 0:001) and lessened or reversed orthostatic symptoms. Furthermore, there was an enhanced response to the cold pressor test and a reduction in forearm blood flow. These findings suggest that indomethacin has a positive effect on systemic vascular resistance.

Administration, Oral↗
PubMed1979

Study of the metabolic effects of bunitrolol (Koe 1366) in angina induced by catecholamine infusion.

In ten angina patients responding with a myocardial anaerobic metabolic pattern to isoproterenol infusion, a new beta-blocking agent, bunitrolol, was effective in normalizing the myocardial lactate extraction ratio. The correlation with lipid metabolism was also interesting because beta-blocker action reduced significantly arterial non-esterified fatty acids (NEFA) level as well as myocardial NEFA extraction. The metabolic behavior suggests the effectiveness of bunitrolol in the treatment of ischemic heart disease.

Angina Pectoris↗
PubMed1978

[Effect of vitamin D and vitamin E on the erythrocyte membrane. I. Effect on in vitro osmolar resistance and lysis].

As in the case of retinol, low doses of cholecalcipherol and alpha-tocopherol "in vitro" increase the osmotic resistance of red blood cells, while high doses have a lytic effect on the erythrocytes of various animal species (e.g.: man, sheep, rabbit, guinea-pig, mouse, rat) with the exception of the chicken. The haemolytic effect of cholecalcipherol is less intense than that of retinol; alpha-tochopherol, while causing even less haemolysis than cholecalcipherol, involves a remarkable loss of K+ from the red cells. Besides these quantitative differences, the mechanism of action of the three vitamins seems somewhat different, as shown by modifications of the suspension medium (e.g.: pH, temperature, presence of proteins and reducing substances) or by treatment of the red cells with trypsin. Our results therefore essentially confirm the hypothesis of Dingle and Lucy of common mechanism of action of liposoluble vitamins on biological membranes.

Cholecalciferol↗
PubMed1978

[The antegrade GAPs (author's transl)].

GAP in a-v conduction is defined as a zone within the cardiac cycle where premature atrial impulses fail to evoke ventricular responses whereas atrial beats of greater and lesser prematurity do. This phenomenon occurs when the effective refractory period (ERP) of a distal site is greater than the functional refractory period (FRP) of a proximal site of the conduction system. To date, Damato and Co. classify antegrade gaps into six types on the basis of blocks location and proximal delay that permits conduction recovery: type I: HPS and AVN; type II: HPS (distal) and HPS (proximal); type III: HPS and His-bundle; type IV: AVN (distal) and AVN (proximal); type V: AVN or HPS and atrium; type pseudo-V: AVN or HPS and antrial miocardium proximal to stimulation site; type VI: HPS and supernormality (no proximal delay). The Authors propose, on the basis of 37 cases of GAP phenomenon observed in 185 electrophysiological studies, a new classification of antegrade gaps, which complete and partially modifies Damato's one. Tyes I-II-II-IV and V are divided into A and B forms according to the type and the site of the distal block. GAP type VI is replaced by Damato's pseudo-V. Two new types are proposed: in the first (type VII) the distal block is in the atrium and the proximal delay is in atrial miocardium proximal to stimulation site; in the second (type VIII), in subjects with pre-excitation, the block is in the accessory pathway and the proximal delay is in atrium.

Adolescent↗
PubMed1977

[Controlled multicentric trial of the antihypertensive agent indapamide].

Two-months' administration of 2.5 mg/day indapamide, preceded and followed by 2 weeks of a placebo, led to a significant fall in pressure values and normalisation of diastolic pressure in a high percentage of 47 subjects, mostly with essential hypertension, in a controlled multi-centre trial. Absence of toxic effects, tolerance and therapeutic activity at low doses recommend the drug for most cases of arterial hypertension.

Adult↗